We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > marginal zone lymphoma

News List

Bayer receives U.S. FDA breakthrough therapy designation for copanlisib for the treatment of marginal zone lymphoma worldpharmanews
May 30, 2019
Bayer announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for copanlisib (Aliqopa™) for the treatment of adult patients with ...
FDA Approves Lenalidomide for Follicular and Marginal Zone Lymphoma americanpharmaceuticalreview
May 30, 2019
On May 28, 2019, the Food and Drug Administration (FDA) approved lenalidomide (REVLIMID®, Celgene) in combination with a rituximab product for previously treated follicular lymphoma (FL) and previously treated marginal zone lymphoma (MZL).
US FDA approves AbbVie’s Imbruvica to treat marginal zone lymphoma pharmaceutical-technology
January 24, 2017
The US Food and Drug Administration (FDA) has approved AbbVie’s Imbruvica (ibrutinib) for the treatment of patients with relapsed / refractory (R/R) marginal zone lymphoma (MZL).